Xcout Intel
GLYCOREX TRANSPLANTATION B competitors & alternatives
The 12 closest competitors and alternatives to GLYCOREX TRANSPLANTATION B among medical devices companies — ranked by similarity to what GLYCOREX TRANSPLANTATION B actually does, not by market-cap band.
Subscribe to see GLYCOREX TRANSPLANTATION B’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About GLYCOREX TRANSPLANTATION B
Glycorex Transplantation AB develops medical devices that utilize proprietary technology to selectively remove specific antibodies from the blood. Its core product, Glycosorb® ABO, enables blood group incompatible organ, stem cell, and heart transplants. Additionally, the company is expanding its applications to include universal blood plasma production and treatments for autoimmune diseases such as rheumatoid arthritis.
GLYCOREX TRANSPLANTATION B at a glance
GLYCOREX TRANSPLANTATION B is a medical devices company headquartered in United Kingdom. Xcout tracks 6 named people at GLYCOREX TRANSPLANTATION B, including Carl-Magnus Schultz (CEO).
GLYCOREX TRANSPLANTATION B leadership
- Carl-Magnus SchultzCEO
- Richard LundinChairman of the board
- Fredrik JohanssonMember of the board
- Kurt NilssonMember of the board
- Lina KarlssonMember of the board
- Roland FrösingMember of the board
Top 12 GLYCOREX TRANSPLANTATION B competitors
Ranked by semantic similarity — how close each company is to GLYCOREX TRANSPLANTATION B by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar medical devices company
Xeltis is a medical technology company that develops bioresorbable cardiovascular implants, such as artificial blood vessels and valves. Utilizing its proprietary Restorex technology, the company's products are designed to be gradually replaced by the patient's own living tissue to treat life-threatening conditions and improve vascular surgery outcomes.
Similar medical devices company
OrganOx is an organ technology company founded as a spin-out from the University of Oxford, United Kingdom. It pioneers liver perfusion technology to address transplant challenges and improve transplant success through innovation and clinical research.
Similar medical devices company
Xvivo Perfusion AB (publ) is a specialized medtech company creating advanced technologies for the preservation and perfusion of organs, tissues, and cells, vital for successful transplantation. Founded in 1998 and headquartered in Gothenburg, Sweden, the company extends its operations across Sweden, the United States, the broader regions of North and South America, Europe, the Middle East, Africa, and the Asia Pacific. Their product line encompasses the XVIVO System (XPS), an integrated, off-the-shelf cardiac bypass system engineered for secure normothermic ex vivo lung perfusion (EVLP). Accompanying this is the XPS Disposable Lung Kit, supplying necessary sterile disposables and pre-packaged components. They also provide STEEN Solution, a uniquely formulated buffered extracellular solution optimized for perfusing isolated donor lungs during EVLP, and Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte solution for organ preservation. Additional offerings include the XVIVO Silicone Tubing Set for efficient flushing of donor lungs during procurement, as well as the XVIVO LS and XVIVO Disposable Lung Set, which together constitute a dedicated EVLP device. Furthermore, Xvivo Perfusion supplies the XVIVO Organ Chamber, a single-use sterile disposable container designed as a temporary holding unit for isolated lungs before transplantation, alongside the single-use, sterile XVIVO Lung Cannula Set.
Similar medical devices company
Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.
Similar medical devices company
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Similar medical devices company
Orthox is a medical device company founded to transform how injuries to cartilage and other hard-to-heal human tissues are treated, with its headquarters located in Oxfordshire, United Kingdom.
Similar medical devices company
SurgaColl is an Irish medical-device company developing collagen-based biomaterial scaffolds for regenerative medicine and tissue repair. Its products are intended for use by healthcare professionals treating patients who need tissue regeneration, including bone or soft-tissue repair.
Similar medical devices company
PolyNovo Limited develops and manufactures synthetic skin substitutes using its proprietary NovoSorb technology. The company provides medical products designed to support wound management and natural healing for healthcare professionals and patients.
Similar medical devices company
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
Similar medical devices company
Vitrolife AB (publ) is a medical technology firm focused on the development, production, and commercialization of a wide array of products for assisted reproductive procedures. Its extensive product range encompasses specialized instruments such as oocyte retrieval needles and micromanipulation pipettes, alongside crucial consumables like sperm processing solutions, IVF culture media and oil, general labware, incubators, cryopreservation materials, and offerings for preimplantation genetic testing. Furthermore, the company supplies sophisticated technological platforms, including the EmbryoScope and Primo Vision time-lapse embryo monitoring systems, complete with compatible dishes and analytical tools. Other advanced solutions include Octax laser and imaging systems, as well as environmental control devices like log and guard systems and wireless sensors. Vitrolife maintains a significant global presence, with operations spanning Europe, the Middle East, Africa, Asia, the Japan and Pacific regions, and both North and South America. The company, headquartered in Gothenburg, Sweden, was established in 1994, originally operating under the name Scandinavian IVF Science before adopting its current identity as Vitrolife AB (publ) in 1998.
Medical Device Manufacturing
Aran Biomedical designs, develops, and manufactures implantable medical devices, components, and finished products for markets such as cardiovascular, neurovascular, and general surgery. The company specializes in medical textiles, biomaterial braiding, PTFE implant covering, coatings, and absorbable material processing. It provides end-to-end development solutions ranging from rapid prototyping to volume manufacturing for medical device companies.
Similar medical devices company
Promimic AB develops and provides surface modification technologies for medical and dental implants, specifically utilizing its HA nano Surface to enhance hydrophilicity and accelerate bone growth. The company serves implant manufacturers in the orthopedic, dental, and biosensor sectors.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of GLYCOREX TRANSPLANTATION B and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for GLYCOREX TRANSPLANTATION Band every competitor above — in one live dashboard.
Subscribe to Xcout Intel →